RxDoctor Payments Data

Huda Sheheitli, MD

Ophthalmology · Minneapolis, MNNPI 1023500584

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by AbbVie at 44.3% of the total. Reporting peaked in 2024 at $1,709 and has fallen 66.5% since, to $572 in 2025.

$3,184in general payments, 2019–2025

Across 26 payments — averaging $122.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Glaukos Corporation$536
  • Alcon$414
  • Sight Sciences, Inc.$318
  • Johnson & Johnson Surgical Vision, Inc.$125
  • Regeneron Healthcare Solutions, Inc.$121
  • plus $259 from 3 others

What the payments were for

  • Consulting fees$1,35042%
  • Food & beverage$1,83458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,184 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$67,539
Medicare patients
204
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate57$22,664
RestasisCyclosporine20$15,313
LumiganBimatoprost23$10,819
Dorzolamide-TimololDorzolamide/Timolol/Pf66$9,507
Brimonidine Tartrate271$7,953
Travoprost48$6,828
Cyclosporine15$6,162
Latanoprost506$5,713
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat318$5,529
TafluprostTafluprost/Pf26$4,779
VyzultaLatanoprostene Bunod11$4,611
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,765
Prednisolone Acetate59$3,626
Brinzolamide13$2,551
Timolol Maleate118$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,410$26,13143 claims
Bausch & Lomb Americas Inc.Vyzulta$71$4,61111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →